2-phenylbenzothiazole has been researched along with Huntington Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayton, S; Bush, AI; Cherny, RA; Finkelstein, DI; Massa, SM; McColl, G | 1 |
| Langbehn, DR | 1 |
1 trial(s) available for 2-phenylbenzothiazole and Huntington Disease
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Biomarkers; Clioquinol; Cognition Disorders; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Placebos; Treatment Outcome | 2015 |
2 other study(ies) available for 2-phenylbenzothiazole and Huntington Disease
| Article | Year |
|---|---|
PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
Topics: Animals; Atrophy; Caenorhabditis elegans; Clioquinol; Corpus Striatum; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Resistance; Huntington Disease; Longevity; Mice; Mice, Transgenic; Motor Skills; Species Specificity | 2012 |
Criteria for success in safety and tolerability trials.
Topics: Clioquinol; Cognition Disorders; Female; Humans; Huntington Disease; Male | 2015 |